14 slides from BioLineRX's technical presentation, Dec 16, 2020
Slide 1: COMBAT Study - Cohort 2 results
COMBAT Study- Cohort 2 results Manuel Hidalgo, M.D., Ph.D. COMBAT Study Principal Investigator December 16th 2020
Slide 2: Disclosure
Disclosure • Founder and Stockholder: Champions Oncology, Inc; Nelum Pharmaceuticals • Stockholder: Agenus, Pharmacyte, InxMed, BioOncotech • Research support from: Erytech, BioExcell, TopAlliance, PanCan • Honorarium from: Agenus, Oncomatrix, InxMed, Takeda, PanCan, AACR, Tolero Pharmaceuticals. •
Slide 3: COMBAT - Study Design
COMBAT - Study Design Main inclusion/exclusion criteria Endpoints ▪ 18 years old and above ▪ ORR according to RECIST 1.1 criteria ▪ Metastatic disease at first diagnosis (Stage IV) ▪ Disease control rate (DCR) ▪ Progressed after first-line gemcitabine-based treatment ▪ Duration of response ▪ No prev
Slide 4: Disposition
Disposition Assessed for eligibility N=55 Screening Failures N=12 Enrolled N=43 Received monotherapy N= 43 Received combination N=39 Evaluable for efficacy N=38 Non-Evaluable Discontinued on Monotherapy due to AE N=4 Lost to FU N=1 Analysis set ITT for Safety N=43 Evaluable for efficacy N=38 4
Slide 5: Baseline characteristics
Baseline characteristics EVALUABLE N=43 Gender Female 44.2%/Male 55.8% Diagnosed at stage 4 97.6% Median age 68 (40-85) ECOG 0/1 31.3%/68.7% % of MSI-H (MSS status tested in 38 0% subjects) % of Patients with Liver Metastasis 74.4% 5
Slide 6: Safety profile
Safety profile ALL Grade≥ 3 Nausea and vomiting 74.4% 18.6% Asthenia 67.4% 16.3% Injection site reactions 55.8% 4.7% Diarrhea 53.5% 14% Appetite disorders 41.9% 9.3% Pruritus 39.5% -- Anemias 37.2% 11.6% Rashes, eruptions and exanthems 30.2% -- Gastrointestinal and abdominal pains 30.2% -- Musculosk
Slide 7: Change from Baseline in Target lesions (N=38)
Slide 8: Change from Baseline in Target lesions (N=38)
COMBAT/Keynote-202 Cohort 2-Change from Baseline in Target lesions (N=38) Progression Stable Disease Partial Response 8
Slide 9: Median Progression Free Survival (mPFS) (N=38)
COMBAT/Keynote-202 Cohort 2 Median Progression Free Survival (mPFS) (N=38) 9
Slide 10: Duration of Clinical benefit
COMBAT/Keynote-202 Cohort 2- Duration of Clinical benefit 10
Slide 11: Median Overall Survival (mOS) (N=38)
COMBAT/Keynote-202 Cohort 2 Median Overall Survival (mOS) (N=38) 11
Slide 12: Safety - Low incidence of Neutropenia and Infections
Safety- Low incidence of Neutropenia and Infections ▪ The triple combination was generally well tolerated ▪ Incidence of AEs is consistent with the profile of each drug, however ▪ The incidence of neutropenia and infections is lower than the expected with chemotherapy alone COMBAT NAPOLI1 Neutropeni
Slide 13: COMBAT Study Results Showed Improvement Across All Endpoints
COMBAT Study Results Showed Improvement Across All Endpoints Meta-analysis IRI based NAPOLI-1 2L Endpoint COMBAT stage IV at diagnosis (n=396) subgroup (n=61) Stage III-IV at diagnosis mOS (mos) 6.5 4.7 5.5 3.1 mPFS (mos) 4.0 2.7 (stage III-IV n=117) ORR (%) 21.2% 16% 8.7% 7.7% cORR (%) 13.2% NA (st
Slide 14: Summary
Summary ▪ COMBAT Study results showed improvement across all endpoints ▪ Despite the triple combination regimen, the incidence of neutropenia and infection is much lower than with standard chemotherapy ▪ The COMBAT results are highly encouraging in light of the extremely challenging population, even